CARE Ratings Ltd Upgraded to Hold by MarketsMOJO on Improved Technicals and Financials

Quality Assessment: Consistency and Financial Strength

CARE Ratings has demonstrated commendable financial discipline and operational consistency, which underpins the upgrade in its quality rating. The company has reported positive results for ten consecutive quarters, a testament to its stable earnings trajectory. Its Return on Capital Employed (ROCE) for the half-year period stands at an impressive 24.14%, indicating efficient utilisation of capital to generate profits. Furthermore, the company maintains a zero average Debt to Equity ratio, highlighting a conservative capital structure with no reliance on debt financing, which reduces financial risk considerably.

Cash and cash equivalents have reached a peak of ₹286.60 crores in the half-year period, providing ample liquidity to support ongoing operations and potential growth initiatives. Profit Before Tax excluding other income (PBT less OI) for the quarter has grown robustly by 33.98% to ₹36.00 crores, reinforcing the company’s operational strength. Additionally, institutional investors hold a significant 54.3% stake, reflecting confidence from sophisticated market participants who typically conduct rigorous fundamental analysis before committing capital.

Valuation: Premium Pricing Amidst Strong Returns

Despite the positive fundamentals, CARE Ratings is currently trading at a premium valuation, which tempers the enthusiasm of some investors. The stock’s Price to Book (P/B) ratio stands at 5.7, a level considered very expensive relative to its peers and historical averages. This elevated valuation is supported by a Return on Equity (ROE) of 17.7%, which is respectable but does not fully justify the premium pricing on its own.

Over the past year, the stock has delivered a total return of 42.39%, significantly outperforming the BSE500 index and the Sensex, which posted returns of 2.71% and -10.78% respectively over the same period. Profit growth has been strong at 35.6%, resulting in a PEG ratio of 0.9, which suggests that the stock’s price growth is reasonably aligned with its earnings growth. However, the company’s net sales and operating profit growth rates over the last five years have been moderate at 14.00% and 18.68% annually, indicating that long-term growth prospects may be somewhat constrained.

Financial Trend: Positive Momentum in Recent Quarters

The financial trend for CARE Ratings has been predominantly positive, supporting the upgrade to a Hold rating. The company’s quarterly performance in Q3 FY25-26 was notably strong, with key profitability metrics showing healthy growth. The consistent declaration of positive results over ten quarters highlights a stable earnings base and effective management execution.

Institutional confidence, as reflected by the 54.3% holding, further validates the company’s financial trajectory. The stock’s returns over various time horizons have been impressive: 42.39% over one year, 142.25% over three years, and 256.82% over five years, all substantially outperforming the Sensex and broader market indices. This consistent outperformance underscores the company’s ability to generate shareholder value over the medium to long term.

However, the relatively modest growth in net sales and operating profit over the past five years suggests that while profitability has improved, top-line expansion remains a challenge. Investors should weigh these factors carefully when considering the stock’s future prospects.

Technical Analysis: Shift from Mildly Bearish to Sideways

The technical outlook for CARE Ratings has improved significantly, which was a key driver behind the upgrade in its investment rating. The technical trend has shifted from mildly bearish to sideways, indicating a stabilisation in price movement and a potential base for future upward momentum.

Weekly technical indicators present a bullish picture: the Moving Average Convergence Divergence (MACD) is bullish, Bollinger Bands are signalling bullish momentum, and the Know Sure Thing (KST) indicator is also positive. Conversely, monthly indicators remain mixed with mildly bearish MACD and KST readings, and no clear signals from the Relative Strength Index (RSI) or On-Balance Volume (OBV).

Daily moving averages remain mildly bearish, suggesting some short-term caution. The Dow Theory signals are neutral to mildly bullish on a monthly basis, while weekly trends show no definitive direction. Overall, the technicals suggest that while the stock is no longer in a downtrend, it has yet to establish a strong upward trajectory, justifying a Hold rating rather than a Buy.

CARE Ratings closed at ₹1,634.60 on 13 March 2026, up 1.74% from the previous close of ₹1,606.65. The stock’s 52-week range is ₹1,057.65 to ₹1,964.80, indicating room for upside but also reflecting volatility.

Comparative Performance: Outperforming Benchmarks

CARE Ratings has delivered exceptional returns relative to the Sensex and broader market indices over multiple time frames. The stock’s one-year return of 42.39% dwarfs the Sensex’s 2.71% gain, while its three-year and five-year returns of 142.25% and 256.82% respectively far exceed the Sensex’s 28.58% and 49.70% returns. Even on a ten-year horizon, the stock has delivered a respectable 81.72% return, though this trails the Sensex’s 207.61% gain over the same period.

This outperformance highlights the company’s ability to generate alpha for investors, particularly in recent years. However, the premium valuation and moderate long-term growth rates suggest that investors should maintain a balanced view, recognising both the strengths and limitations of the stock’s outlook.

Conclusion: A Cautious Upgrade Reflecting Balanced Prospects

The upgrade of CARE Ratings Ltd from Sell to Hold reflects a balanced assessment of its current fundamentals and market positioning. Improvements in technical indicators, consistent positive financial results, strong institutional backing, and impressive recent returns have all contributed to this more favourable rating. However, the company’s premium valuation, moderate long-term growth rates, and mixed technical signals counsel caution.

Investors should consider CARE Ratings as a stable, quality player within the capital markets sector with potential for steady returns, but one that may not offer significant upside in the near term given its valuation and growth profile. The Hold rating appropriately captures this nuanced outlook, signalling neither a strong buy opportunity nor a sell signal at this juncture.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →